Skip to content

Evaluation of administration of capsule dosage form preparation of Dracocephalum kotschyi extract on biochemical and hematological parameters.

Comparison of biochemical and hematological parameters prior and after oral administration of Dracocephalum kotschyi capsules in human healthy volunteers.

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200810048352N4
Enrollment
15
Registered
2024-12-30
Start date
2024-11-21
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological and biological factors.

Interventions

Intervention 1: Intervention group: Receiving Darcocephalum kotschyi capsule (50mg) orally three times daily for 4 weeks. Dracocephalum capsule are made in Dr Bahri pharmaceutical company (Isfahan) an

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers Male

Exclusion criteria

Exclusion criteria: Females Volunteers on drug treatment (any drugs, herbal or chemical) Non healthy subjects (any disease diagnosed by physician and blood analysis) Children (under 18) and old subjects (above 50) Smoking subjects

Design outcomes

Primary

MeasureTime frame
Complete blood cell counting. Timepoint: At the beginning of study and 28 days after consumption of Zaringiah capsule. Method of measurement: Device K-1000 Hematology Analyzer.;Blood biochemical factors. Timepoint: At the beginning of study and 28 days after consumption of Zaringiah capsule. Method of measurement: Spectrophotometry technique.;Blood parameters for hepatic and renal function. Timepoint: At the beginning of study and 28 days after consumption of Zaringiah capsule. Method of measurement: Colorimetric/fluorometric assay.

Secondary

MeasureTime frame
General physical condition. Timepoint: Daily for 28 days. Method of measurement: Questioning and if necessary clinical examination.;Central nervous system effects including sleep and sedativety. Timepoint: Daily for 28 days. Method of measurement: Visual analogue scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hassan Sadraei

Esfahan University of Medical Sciences

sadraei@pharm.mui.ac.ir+98 31 3792 7086

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026